We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Capital wins contracts; 4D pharma pauses enrolment

Fri, 01st Jul 2022 20:05

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Friday and not separately reported by Alliance News:

----------

ADM Energy PLC - London-based natural resource investor - Notes PetroNor E&P Ltd extends the long-stop date for Panoro Energy ASA to sell 100% ownership in OML-113 to PetroNor. Expects transaction to complete within 14 days. "ADM Energy holds a 9.2% profit interest in the Aje field in OML 113, which covers an area of 835 square kilometres offshore Nigeria. Aje has multiple oil, gas and gas condensate reservoirs in the Turonian, Cenomanian and Albian sandstones with five wells drilled to date. It currently has two producing wells, Aje-4 in the Cenomanian and Aje-5 in the Turonian," ADM explains.

----------

Primorus Investments PLC - London-based investment firm focused on small and mid cap firms in financial services, technology and natural resources - Notes investee Alteration Earth PLC begins trading on the Main Market of the London Stock Exchange. Primorus holds 28% of ALTE's share capital, at 5.0 million shares, having invested GBP100,000 in its seed round, and GBP250,000 in its subscription round. Also says it has acquired 1.0 million shares in AIM-listed Landore Resources Ltd at 22.60 pence each, for GBP225,978 in total. Landore is a holding company for its 100% owned subsidiary Landore Resources Canada Inc, which is an acquirer, developer and explorer of precious and base metal projects in Eastern Canada.

----------

San Leon Energy PLC - Dublin-based oil and gas production, development and exploration company focused on Nigeria - In discussions with Decklar Resources Ltd to extend the option period for the firm to increase its shareholding in Decklar to 15% from 11%. This would entail a further loan of USD2.5 million, and the previous deadline for the option was Thursday.

----------

4D Pharma PLC - Leeds, England-based pharmaceutical company - Pauses recruitment of new patients in its ongoing clinical studies, citing the firm being put into administration as the reason for doing so. Will affect three studies into MRx0518, one study of MRx-4DP0004, and one study of MRx0005 or MRx0029. "4D pharma is working with the administrators to enable an exit from administration as soon as possible and, in the event that the company does exit administration, currently plans to recommence recruitment so long as additional capital funding is secured. Further announcements will be made in due course," the firm says.

----------

Petropavlovsk PLC - Russian gold producer - Says MHA MacIntyre Hudson, the UK member of Baker Tilly International has resigned as its external auditor. Had changed its accounting reference period to February 28 year-end from December 31, as it considered completion of the audit "unlikely". The firm maintains this position.

----------

PCF Group PLC - London-based specialist bank - Signs agreement with majority shareholder Somers Ltd for subscription of around GBP1.4 million in 27.9 million new shares. Somers' stake in the firm will increase to 73.2% from 70.8% after the new shares are admitted, expected on Monday. Reiterates intention to raise additional capital through open offer for up to EUR8 million, in which Somer is not expected to participate.

----------

Seed Innovations Ltd - Guernsey-based wellness and life sciences company - Notes announcement from investee Little Green Pharma Ltd that in the nine months to March 31, its revenue grew by 50% year-on-year. Seed holds a 3.1% stake in LGP. "It has been an exceptional year for LGP, as it continued its growth in Australia and advanced its strategy to expand into other markets. During the period, LGP became a leading cannabis company in the European Union with its GMP-licensed Danish facility and its continued development of its supply channels into new markets such as Italy and Denmark," says Alfredo Pascual, vice president of Investment Analysis.

----------

Pembridge Resources PLC - London-based copper-focused mining company - Receives second repayment of CAD1 million due to it from Minto Metals Corp. Pembridge lent CAD4 million in total to Minto to fund Minto's surety account, in 2019 and 2020. The loan has an interest rate of 8%, and is due in quarterly instalments of CAD1 million over 2022. The first repayment was received in March, as planned. "With this second CAD1 million repayment from Minto, Pembridge is in a much stronger cash position, which will improve further with the repayments which are still to come," says Chair & Chief Executive Officer Gati Al-Jebouri.

----------

Capital Ltd - Africa-focused mining services provider - Wins new contracts for drilling and laboratory services. Its Tanzanian subsidiary CMS (Tanzania) Ltd wins a three-year comprehensive drilling services contract with AngloGold Ashanti Ltd. The contract "further cements" the long-term relationship between the two parties, which started back in 2006. Expects the new deal to generate USD150 million over the three-year term, which makes it the second-largest award of new business in Capital's history, the firm says. Also wins first contract with B2Gold Corp at Fekola gold mine, for reverse circulation drilling services, and a two-year extension to MSALABS contract for onsite laboratory services with Kinross at the Tasiast gold mine in Mauritania. "We are pleased to maintain our long-standing relationship with AngloGold Ashanti at their Geita Gold Mine with the award of this revised and expanded long-term contract that will extend our relationship to almost 20 years. The full range of drilling services included in the contract is not only a reflection of our excellent operational and safety performance, but also highlights our strategy to increase our service offering with long-term mine-site based clients," says Executive Chair Jamie Boyton.

----------

Tristel PLC - Cambridgeshire-based maker of infection prevention, contamination control and hygiene products - Submits its De Novo request for approval to the US Food & Drug Administration for Tristel Duo ULT, a high-level disinfectant foam for ultrasound probes. "Ultrasound probe disinfection is one of Tristel's most important areas of focus within the hospital infection prevention market and accounts for approximately 40% of the company's global revenue, which analysts forecast at GBP28 million for the current financial year," the company says. Says timeframe for FDA decision is 150 days, but additional data requests are commonplace, with the average duration for review and approval is around 11 months.

----------

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
15 Feb 2023 14:21

IN BRIEF: 4D Pharma shares cancelled from trading on London's AIM

4D Pharma PLC - Leeds-based pharmaceutical firm - Notes cancellation of its shares on AIM from Thursday, after it entered into administration in June 2022.

Read more
3 Feb 2023 15:17

TRADING UPDATES: GCP Infra hails NAV rise; Jadestone profits from oil

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
9 Jan 2023 15:58

UK shareholder meetings calendar - next 7 days

Tuesday 10 January 
Valereum Blockchain PLCAGM
Wishbone Gold PLCAGM
Wednesday 11 January 
AB Dynamics PLCAGM
Asos PLCAGM
Edge Performance VCT PLCGM re deed of release
Hurricane Energy PLCAGM
Induction Healthcare Group PLCAGM
MetalNRG PLCGM requisitioned to remove chair and CEO from board
Synthomer PLCGM re sale of laminates business
Thursday 12 January 
JPMorgan Japanese Investment Trust PLCAGM
Friday 13 January 
eEnergy Group PLCGM re shareholder resolution to adopt the 2022 Accounts
Monday 16 January 
4D Pharma PLCGM re update on administration and suspension of trading
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
30 Dec 2022 17:21

4D Pharma seeks approval for equity fundraise to lift suspension

(Alliance News) - 4D Pharma PLC on Friday said it was seeking shareholder approval for a USD15.0 million cash raise, as it works to lift its suspension and restore its shares to trading.

Read more
16 Nov 2022 17:00

4D Pharma says trial results show Blautix eases IBS symptoms

(Alliance News) - 4D Pharma PLC said on Wednesday that its Blautix phase 2 clinical trial results showed the treatment had a positive effect on sufferers of irritable bowel syndrome

Read more
24 Aug 2022 11:44

IN BRIEF: 4D Pharma publishes pre-clinical research for autism

4D Pharma PLC - Leeds, England-based pharmaceutical company - Releases its publication of pre-clinical research on mice regarding live biotherapeutic MRx0006 for the treatment of autism spectrum disorder. Says research shows LBP MRx0006 can attenuate core behavioural deficits in a mouse model of autism, improving social deficits, repetitive and anxiety-like behaviours. "Mechanistically, MRx0006 increased in the brains of ASD mice the expression of neuropeptide hormones known to regulate social and anxiety behaviour," 4D Pharma adds.

Read more
5 Aug 2022 14:58

TRADING UPDATES: 4D Pharma warns of wind-up; Star Phoenix files claim

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Wednesday and not separately reported by Alliance News:

Read more
28 Jun 2022 21:23

IN BRIEF: 4D Pharma shares to be delisted from Nasdaq

4D Pharma PLC - Leeds, England-based pharmaceutical company - Says it has received written notice from the Nasdaq Stock Market that its securities will be delisted from Nasdaq. Accordingly, trading of its shares will be suspended from the opening of business on July 7. Nasdaq staff cited 4D's announcement that it had been placed into administration on Friday as raising "public interest concerns". The exchange also mentioned concerns regarding the residual equity interest of existing shareholders of listed securities.

Read more
24 Jun 2022 19:09

IN BRIEF: 4d Pharma faces uncertain future as loan repayment due

4d Pharma PLC - Leeds, England-based pharmaceutical company - Says it has "no immediate certainty" of how it will repay the USD13.9 million loan facility it has with Oxford Finance LLC.

Read more
24 Jun 2022 14:33

IN BRIEF: 4d Pharma suspends trading immediately, pending announcement

4d Pharma PLC - Leeds, England-based pharmaceutical company - Says it has ordered an immediate suspension of trading in the company's shares on AIM pending a further announcement.

Read more
24 Jun 2022 12:35

4D Pharma requests immediate suspension of its shares

(Sharecast News) - Biotherapeutics developer 4D Pharma requested an immediate suspension of trading in its shares on Friday.

Read more
21 Jun 2022 16:05

UK shareholder meetings calendar - next 7 days

Wednesday 22 June 
ASA International Group PLCAGM
Atalaya Mining PLCAGM
Bonhill Group PLCAGM
Chapel Down Group PLCAGM
Churchill China PLCAGM
Downing Renewables & Infrastructure Trust PLCGM re share issue
Ecofin US Renewables Infrastructure Trust PLCAGM
EJF Investments LtdAGM
Frenkel Topping Group PLCAGM
Good Energy Group PLCAGM
Honeycomb Investment Trust PLCAGM
ICG-Longbow Senior Secured UK Property Debt Investments LtdAGM
Intelligent Ultrasound Group PLCAGM
Iofina PLCAGM
John Wood Group PLCAGM
Kingfisher PLCAGM
LXi REIT PLCGM
Menhaden PLCAGM
North Atlantic Smaller Cos Investment Trust PLCAGM
Pennant International Group PLCAGM
Plant Health Care PLCAGM
Skillcast Group PLCAGM
Team PLCAGM
Tribal Group PLCGM re final dividend
Trident Royalties PLCAGM
Vertu Motors PLCAGM
Wentworth Resources PLCAGM
Thursday 23 June 
Avacta Group PLCAGM
Anglo Asian Mining PLCAGM
Card Factory PLCAGM
Cordiant Digital Infrastructure LtdAGM
Downing Renewables & Infrastructure Trust PLCGM re initial placing & open offer
Eight Capital Partners PLCGM re aligning 2022 bonds with 2026 bonds
GENinCode PLCAGM
Ideagen PLCGM re takeover by Hg Pooled Management Ltd
Longboat Energy PLCAGM
Oxford Nanopore Technologies PLCAGM
Puma VCT 13 PLCGM re cancellation of listing & liquidation
RBG Holdings PLCAGM
Tandem Group PLCAGM
Union Jack Oil PLCAGM
Zinnwald Lithium PLCAGM
Friday 24 June 
AFC Energy PLCGM re fees for non-executive directors
Avast PLCAGM
Devolver Digital IncAGM
Entain PLCAGM
Gulf Keystone Petroleum LtdAGM
Hawkwing PLCAGM
Invesco Bond Income Plus LtdAGM
Life Science REITAGM
Northcoders Group PLCAGM
Princess Private Equity Holding LtdAGM
Monday 27 June 
Anglo-Eastern Plantations PLCAGM
Celadon Pharmaceuticals PLCAGM
Cizzle Biotechnology Holdings PLCAGM
Echo Energy PLCAGM
Medica Group PLCAGM
Pelatro PLCAGM
Surgical Innovations Group PLCAGM
Warpaint London PLCAGM
Tuesday 28 June 
4D Pharma PLCAGM
Acceler8 Ventures PLCAGM
Airtel Africa PLCAGM
Alina Holdings PLCAGM
Aquila Energy Efficiency Trust PLCAGM
Attraqt Group PLCAGM
Bay Capital PLCAGM
Capital & Counties Properties PLCAGM
CMO Group PLCAGM
Corre Energy BVAGM
Creo Medical Group PLCAGM
Futura Medical PLCAGM
Gama Aviation PLCAGM
ICG Enterprise Trust PLCAGM
ImmuPharma PLCAGM
IQE PLCAGM
Katoro Gold PLCAGM
Rockhopper Exploration PLCAGM
Sound Energy PLCAGM
TP Group PLCAGM
UK Oil & Gas PLCAGM
Volvere PLCAGM
Zegona Communications PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
27 May 2022 10:46

4D Pharma reports progress in bladder cancer trial

(Sharecast News) - Live biotherapeutics developer 4D Pharma announced progress in the phase 2 clinical trial in bladder cancer on Friday.

Read more
27 May 2022 09:31

IN BRIEF: 4D Pharma plans to test MRx0518 in combination with Bavencio

4D Pharma PLC - Leeds, England-based pharmaceutical company - Plans to conduct a phase II study to assess the safety of MRx0518 in combination with Bavencio. Says the study will be conducted in patients with unresectable locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. Says previous data about MRx0518 supports the potential of this combination to "significantly enhance and improve" outcomes for patients, beyond treatment with Bavencio alone. Bavencio is an antibody medication for the treatment of urothelial carcinoma.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.